HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31

HARROW, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$27.68+0.40 (+1.47%)

Close on Oct 19, 2026

Market cap: $1.03B
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$272.30MFY2025, +134.2% a year since FY2013

Where these numbers come from

Parsed from the XBRL in Harrow's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Mar 18, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HROW.

Revenue growth21.1% · median 13.2%

Gross margin73.3% · median 50.6%

Operating margin-1.0% · median 2.3%

Net margin-13.5% · median -11.7%

Company	Revenue	Growth
ANIP	$978.38M	+30.9%
OPK	$587.90M	-11.5%
MNKD	$393.63M	+30.5%
HROW	$275.59M	+21.1%
KMDA	$191.85M	+13.2%
KPTI	$146.62M	+6.8%

Company

Next earnings (est.): Nov 9, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 373
Held by institutions: 57.4%
Auditor: KMJ Corbin & Company LLP
SEC CIK: 1360214

Advertisement
300 × 250